Equity · Healthcare
ABCL
NASDAQAbCellera Biologics (ABCL)
The line runs 9 USD on 10 August through 11.88 USD on 6 November, on a scale from 8 to 16. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.6B USD
- Revenue, year to Dec 2025
- 75.1M USD
- EPS, diluted, year to Dec 2025
- −0.49 USD
- 52-week range
- 3 USD – 14.83 USD
- Avg volume
- 308.5K
- Mentions, 30 days
- 1
as of Nov 6, 2026
Have AbCellera Biologics (ABCL) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, AbCellera Biologics insiders reported 4 open-market purchases and no sales (SEC Form 4).
Form 4, 90 days to 9 Nov 2026, newest reported trade 24 Aug 2026
Buys 4Sells 0Net bought $1.55MOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 24 Aug 2026 | Hayden Michael RDirector | Buy | 53,613 | 570K USD |
| 18 Aug 2026 | Montalbano John S.Director | Buy | 10,000 | 110K USD |
| 14 Aug 2026 | Booth AndrewChief Financial Officer | Buy | 37,200 | 384K USD |
| 12 Aug 2026 | Hayden Michael RDirector | Buy | 46,387 | 481K USD |
| Bought | 4 open-market purchases | 147,200 | $1.55M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Aug 2026 | Hayden Michael RDirector | Gift | 50,000 |
Which funds hold AbCellera Biologics (ABCL)?
9 of the 45 institutional funds we track reported a AbCellera Biologics position for the quarter ended 30 Jun 2026 — a combined 398.7M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 33,012,138 | 259.1M USD | +9.0% |
| Two Sigma Investments | Held (±25%) | 10,437,431 | 81.9M USD | −1.2% |
| Tudor Investment Corp | Held (±25%) | 2,063,191 | 16.2M USD | −9.3% |
| Marshall Wace | Added | 1,902,191 | 14.9M USD | +428.9% |
| Citadel Advisors | Held (±25%) | 1,586,512 | 12.5M USD | +16.6% |
| Renaissance Technologies | Trimmed | 990,929 | 7.8M USD | −34.4% |
| Millennium Management | Trimmed | 518,571 | 4.1M USD | −59.9% |
| Man Group | New position | 228,979 | 1.8M USD | |
| D. E. Shaw & Co. | New position | 45,431 | 357K USD | |
| Point72 Asset Management | Exited |
What has been filed or recorded for AbCellera Biologics (ABCL)?
The filings we hold for AbCellera Biologics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 06 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,463 shares | 20K USD notional · <0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 403 shares | 6K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 20,506 shares | 285K USD notional · 0.007% of shares out |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 9,515 shares | 132K USD notional · 0.003% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.18 USD | Revenue $4M |
| 30 Jun 2026 | Financials | Total assets | 1.3B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 896.0M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.14 USD | Revenue $8M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.49 USD | Revenue $75M |
| 31 Dec 2025 | Financials | Revenue | 75.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −146.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.49 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.19 USD | Revenue $9M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.12 USD | Revenue $17M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.15 USD | Revenue $4M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.55 USD | Revenue $29M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.17 USD | Revenue $7M |
What is Reddit saying about AbCellera Biologics (ABCL)?
Reddit mentioned ABCL 1 times in the 30 days to 8 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 8 November 2026.
30-day window, Method
Mentions, 30 days 1Communities 1
How do Reddit mentions of AbCellera Biologics (ABCL) compare with its price?
Share ↗
Where AbCellera Biologics (ABCL) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/investing | 100% | 1 | +0.19 |
AbCellera Biologics (ABCL): frequently asked questions
What did AbCellera Biologics shares close at?
AbCellera Biologics closed at 11.88 USD on 6 Nov 2026, up 10.51% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is AbCellera Biologics’ market cap?
AbCellera Biologics is worth 3.6B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is AbCellera Biologics’ revenue?
AbCellera Biologics reported revenue of 75.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have AbCellera Biologics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, AbCellera Biologics insiders reported 4 open-market purchases and no sales (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own AbCellera Biologics?
9 of the 45 funds we track reported a AbCellera Biologics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Two Sigma Investments and Tudor Investment Corp. See Funds
When did AbCellera Biologics last report earnings?
AbCellera Biologics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.18 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about AbCellera Biologics?
AbCellera Biologics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings